CJC-1295 No DAC
Also known as: Modified GRF 1-29, Mod GRF, CJC-1295 without DAC
CJC-1295 No DAC is a synthetic growth hormone-releasing hormone (GHRH) analog that stimulates natural growth hormone production without the drug affinity complex, requiring more frequent administration but offering precise timing control.
CJC-1295 No DAC is a 3367.97 Da research peptide. CJC-1295 No DAC is a synthetic growth hormone-releasing hormone (GHRH) analog that stimulates natural growth hormone production without the drug affinity complex, requiring more frequent administration but offering precise timing control.
Also called: Modified GRF 1-29, Mod GRF, CJC-1295 without DAC
3367.97
Molecular Weight
Daltons
1
Strong Evidence
benefits
3
Studies Cited
peer-reviewed
100-200
Typical Dose
mcg
Overview
CJC-1295 No DAC represents a modified version of growth hormone-releasing hormone designed to enhance the body's natural growth hormone production. Unlike its DAC counterpart, this peptide lacks the drug affinity complex that extends half-life, resulting in a shorter duration of action but allowing researchers greater control over timing and pulsatile release patterns. The peptide works by binding to GHRH receptors in the anterior pituitary gland, triggering the release of endogenous growth hormone in a more physiological manner. This approach maintains the natural circadian rhythm of growth hormone secretion while amplifying peak levels. Research applications focus on understanding growth hormone dynamics, body composition changes, and metabolic effects. The shorter half-life makes it particularly useful for studying acute growth hormone responses and optimizing injection timing protocols.
Key Takeaways: CJC-1295 No DAC
- Strongest evidence supports CJC-1295 No DAC for growth hormone stimulation
- Research doses typically range from 100 to 200 mcg via subcutaneous
- 1 benefits with strong evidence, 3 moderate, 2 preliminary
- Half-life: 30 minutes
- 3 cited research studies in this guide
Mechanism of Action
CJC-1295 No DAC binds to growth hormone-releasing hormone receptors on somatotroph cells in the anterior pituitary gland, activating adenylyl cyclase and increasing cyclic adenosine monophosphate levels. This cascade triggers calcium influx and stimulates the synthesis and release of growth hormone. The peptide mimics natural GHRH but with enhanced stability against enzymatic degradation, particularly from dipeptidyl peptidase-IV.
Research Benefits
CJC-1295 No DAC at a Glance
CJC-1295 No DAC binds to growth hormone-releasing hormone receptors on somatotroph cells in the anterior pituitary gland, activating adenylyl cyclase and increasing cyclic adenosine monophosphate levels.
Growth hormone stimulation
Strong EvidenceIncreases endogenous growth hormone release by 2-10 fold above baseline levels through direct GHRH receptor activation, maintaining physiological pulsatile patterns while amplifying peak concentrations.
Enhanced protein synthesis
Moderate EvidencePromotes muscle protein synthesis rates through growth hormone-mediated IGF-1 elevation, leading to improved nitrogen retention and lean tissue accretion in research models.
Fat oxidation acceleration
Moderate EvidenceStimulates lipolysis and fatty acid oxidation through growth hormone's metabolic effects, potentially reducing adipose tissue mass while preserving lean body mass.
Bone density support
Moderate EvidencePromotes osteoblast activity and bone formation through growth hormone and IGF-1 pathways, potentially improving bone mineral density over extended periods.
Sleep quality improvement
PreliminaryMay enhance slow-wave sleep phases when timed appropriately, as growth hormone release naturally peaks during deep sleep stages and influences sleep architecture.
Recovery enhancement
PreliminaryAccelerates tissue repair and recovery processes through growth hormone's anabolic effects on protein synthesis, collagen production, and cellular regeneration.
Research Dosing Protocols
Research Purposes Only: All content is for informational and research purposes only. This site does not provide medical advice, diagnosis, or treatment. Consult a qualified healthcare professional before using any peptide or supplement.
| Research Protocol | Dose Range | Route |
|---|---|---|
| Growth hormone stimulation | 100–200 mcg | subcutaneous |
| Body composition research | 200–300 mcg | subcutaneous |
Frequency
1-3 times daily
Timing
Pre-workout, before meals, or before bed
Cycle Length
8-12 weeks
Research Notes
- 1Administer 30 minutes before meals to avoid blunting growth hormone response
- 2Consider timing with natural growth hormone peaks for synergistic effects
- 3Rotate injection sites to prevent lipodystrophy
- 4Fast for 2-3 hours post-injection when possible
Reconstitution Guide
Standard Reconstitution
Vial Size
2 mg
Bacteriostatic Water
2 mL
Concentration
10 mcg
per 0.1 mL (10 units)
Step-by-Step Guide
Gather Materials
CJC-1295 No DAC vial, bacteriostatic water, alcohol swabs, insulin syringes.
Equilibrate Temperature
Remove the vial from storage and allow it to reach room temperature (5-10 minutes).
Sanitize
Swab the rubber stopper of both the peptide vial and bacteriostatic water vial with alcohol.
Draw Water
Draw 2 mL of bacteriostatic water into a syringe.
Add Water to Vial
Insert the needle into the peptide vial and direct the water stream against the glass wall — not directly onto the powder.
Mix Gently
Swirl the vial gently until the powder is fully dissolved. Never shake. The solution should be clear and colorless.
Store Properly
Refrigerate at 2-8°C refrigerated. 30 days reconstituted.
Storage Temperature
2-8°C refrigerated
Shelf Life
30 days reconstituted
Important Notes
- •Use bacteriostatic water for reconstitution
- •Inject water slowly down vial wall to prevent foaming
- •Swirl gently, never shake vigorously
- •Store reconstituted solution in refrigerator
- •Allow to reach room temperature before injection
CJC-1295 No DAC Dosing Calculator
Calculate daily intake, cycle totals, and vials needed with pre-filled protocols →
CJC-1295 No DAC Reconstitution Calculator
Calculate concentration, syringe units, and doses per vial with auto-filled values →
Safety & Side Effects
Reported Side Effects
- !Injection site reactions (redness, swelling)
- !Headaches
- !Flushing or warmth sensations
- !Dizziness
- !Nausea
- !Fatigue or drowsiness
- !Water retention
- !Joint discomfort
- !Numbness or tingling in extremities
- !Potential hypoglycemia
Potential Interactions
- ⚡Insulin and diabetes medications (may affect glucose metabolism)
- ⚡Corticosteroids (may blunt growth hormone response)
- ⚡Thyroid hormones (synergistic metabolic effects)
- ⚡Somatostatin analogs (direct antagonistic effects)
- ⚡Beta-blockers (may influence growth hormone release)
Important: Side effects and interactions listed here are compiled from published research and community reports. This is not a complete list. No formal drug interaction studies have been conducted for most research peptides. Always consult a qualified healthcare provider.
Research Studies
The following studies are referenced in this profile. PubMed IDs are provided where available for independent verification.
Pharmacokinetics and pharmacodynamics of CJC-1295, a long-acting analog of GHRH, in healthy men
Single-dose study demonstrating dose-dependent increases in growth hormone and IGF-1 levels with extended duration of action compared to native GHRH.
Growth hormone-releasing hormone analogs: therapeutic applications and safety considerations
Comprehensive review of GHRH analogs including modified forms, discussing therapeutic potential and development challenges.
Effects of growth hormone-releasing hormone on growth hormone secretion in aging
Investigation of GHRH responsiveness across age groups, showing maintained efficacy in stimulating growth hormone release despite age-related declines.
Note: This is not an exhaustive list of all published research. Studies are selected for relevance and quality. Click PubMed IDs to verify sources independently. Inclusion does not imply endorsement of the peptide for any clinical use.
Frequently Asked Questions
CJC-1295 No DAC has a much shorter half-life (30 minutes vs 6-8 days) requiring multiple daily injections but allowing precise timing control and maintaining natural pulsatile growth hormone patterns.
Most research protocols use 1-3 injections daily, timed before meals, workouts, or bedtime to align with natural growth hormone release patterns and maximize effectiveness.
Unlike synthetic growth hormone, CJC-1295 No DAC stimulates natural production through GHRH receptors and is less likely to cause feedback suppression, though extended high-dose use may still affect natural patterns.
Common timing includes pre-workout (30-45 minutes before), before meals, or before bed to align with natural growth hormone peaks and optimize metabolic effects.
Growth hormone elevation occurs within 30-60 minutes of injection, but noticeable body composition changes typically require 4-6 weeks of consistent use in research settings.
Yes, both powder and reconstituted solution should be stored at 2-8°C. Reconstituted peptide maintains potency for approximately 30 days under proper refrigeration.
CJC-1295 No DAC stimulates natural production maintaining physiological patterns, while synthetic GH provides direct hormone replacement. Each has different research applications and risk profiles.
Most common side effects include injection site reactions, headaches, flushing, and potential water retention. Serious adverse effects are rare in research doses.
Research & Educational Use Only
All content is for informational and research purposes only. This site does not provide medical advice, diagnosis, or treatment. Consult a qualified healthcare professional before using any peptide or supplement.
The information presented here is compiled from published research studies and is intended for informational purposes only. Individual results may vary. Always consult with a licensed healthcare provider.